HotSpot Therapeutics Completes $65 Million Series B Financing to Advance Pipeline of Novel Allosteric Medicines
May 21, 2020•about 5 years ago
Amount Raised
$65 Million
Round Type
series b
Description
HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting nature's regulatory sites, today announced the completion of a $65 million Series B financing. The financing round was led by S.R. One, Limited and included funds managed by Tekla Capital Management, MRL Ventures Fund, Solasta Ventures and Brace Pharma (via affiliate Cleva Pharma), along with co-founding investors Atlas Venture and Sofinnova Partners. Concurrent with the financing, Jill Carroll, Partner at S.R
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech